Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy
NCT00217139 is registered in ClinicalTrials.gov with BioWest Therapeutics Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy
- Lead sponsor
- BioWest Therapeutics Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- September 30, 2006
- Enrollment
- 60
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.